Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meldex to launch new OTC treatments
While Phytosulin is for people who may be resistant to insulin, DAOsin is for the treatment of histamine intolerance, an under-estimated and under-diagnosed condition which can lead to
While Phytosulin is for people who may be resistant to insulin, DAOsin is for the treatment of histamine intolerance, an under-estimated and under-diagnosed condition which can lead to
These virus types are responsible for more than 98% of gastroenteritis disease in Europe during the first two years of life. Results from this multi-center, randomized, double-blind, placebo-controlled
NanoString has stated that it is preparing for the commercial launch of its nCounter analysis system. Accelr8 has also announced that Schott Nexterion has purchased an OptiChem license
The collaboration is supported by a Wallonia (BioWin) research grant that was announced in April 2007. Financial details of the agreement have not been disclosed. Jim DiGuiseppi, chief
At the same time, Insight Agents has presented a business model, which includes a range of services to radiologists. These include top purchase conditions from one of Europe’s
The Drystar Axys is a multi-application, direct digital imager (DDI) delivering mammography-quality images with 508 dpi image resolution, very short access time, and full flexibility with two film
Encysive received European Union marketing authorization for Thelin from the European Commission in August 2006. The European Commission’s centralized licensing procedure permits Encysive to market Thelin in all
The initial cash consideration payable by DCC is E16 million, including net cash acquired of E3.5 million. Further consideration will be payable up to a maximum of E11.8
Based on a review of the clinical development program and the decision not to file a new drug application for bladder cancer in the US, coupled with an
Together with the E150 million equity investment made in September 2007, this payment brings the cash received to date by Intercell under this strategic alliance with Novartis to